Abstract

Small cell carcinoma of the bladder is a rare type of bladder malignancy. Based on most of the existing studies, there is an observed male predominance, usually in their sixties or seventies, and they are more likely to have a history of smoking. Additionally, there is a higher predilection for Caucasians (versus non-Caucasians). The most common presenting complaint is painless macroscopic hematuria. However, other presenting symptoms also include dysuria, difficulty voiding, weight loss, abdominal pain, nocturia, and urinary frequency. It is not uncommon to have a history of frequent urinary tract infections, ureteral obstruction, and paraneoplastic syndromes. Cystoscopy is the "gold standard" for evaluation of urinary tract lining, especially in conjunction with narrow-band imaging and biopsy. Transurethral resection of the bladder tumor (TURBT) is the next step in diagnosis and treatment that allows to precisely evaluate pathology and the extent of bladder wall involvement, and is a sufficient surgical approach for the treatment of non-muscle invasive tumors. Once tumor pathology is confirmed, a treatment plan is determined based on the staging. Although both lung and bladder small cell carcinoma have similarities in pathogenesis, genomic alterations in small cell carcinoma of the bladder are more similar to that of urothelial cancer rather than small cell lung cancer. As this is a rare subtype and only a few reported cases are available, no standard treatment regimen has been established. In localized disease, neo-adjuvant platinum-based chemotherapy with cystectomy has been shown to provide the best result in retrospective studies. As this type of cancer has a poor prognosis, in metastatic disease, palliative chemotherapy is offered. Here we present one such case of small cell carcinoma of the bladder and review the current literature.

Highlights

  • Small cell carcinoma of the bladder is a neuroendocrine epithelial tumor that comprises less than 1% of bladder cancers

  • Histologic evaluation of biopsy specimen obtained from right bladder base revealed small cell carcinoma: immunohistochemical stains were performed on block A1 and showed tumor cells positive for thyroid transcription factor 1 (TTF1), chromogranin, and synaptophysin, while CK7, CK20, CD56, and GATA3 were negative (Figures 1-3)

  • Other presenting symptoms include dysuria and urinary frequency [4]. Both lung and bladder small cell carcinoma have similarities in pathogenesis, it has been observed that genomic alterations in small cell carcinoma of the bladder resemble more that of urothelial cancer than small cell lung cancer

Read more

Summary

Introduction

Small cell carcinoma of the bladder is a neuroendocrine epithelial tumor that comprises less than 1% of bladder cancers. Once tumor pathology is confirmed, a treatment plan is determined based on the presence or absence of metastases As this is a rare subtype and only a few reported cases are available, no standard treatment regimen has been established. Histologic evaluation of biopsy specimen obtained from right bladder base revealed small cell carcinoma: immunohistochemical stains were performed on block A1 and showed tumor cells positive for thyroid transcription factor 1 (TTF1), chromogranin (focal), and synaptophysin (focal), while CK7, CK20, CD56, and GATA3 were negative (Figures 1-3). Computed tomography (CT) revealed an enlarged irregular appearing prostate gland protruding into the bladder base (site of biopsy-proven small cell carcinoma), bladder outlet obstruction with circumferential thickening of the urinary bladder wall, and a questionable invasion of the anterior wall of the rectum (Figure 4).

Discussion
Findings
Conclusions
Disclosures
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.